Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

ClinicalTrials.gov ID: NCT02732899

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02732899. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Sirolimus in Conjunction With EYLEA® (Aflibercept) Versus EYLEA® Alone for Exudative AMD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA in subjects with exudative age related macular degeneration (AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous intravitreal anti-vascular endothelial growth factor (antiVEGF) treatment.

Study identification

NCT ID: NCT02732899
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Enrollment: 20 participants

Conditions and interventions

Conditions

Exudative Age Related Macular Degeneration

Interventions

Sirolimus Drug
EYLEA Drug

Drug

Eligibility (public fields only)

Age range: 50 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2016 (Type not available)
Primary completion: Mar 20, 2017 (Actual)
Completion: Apr 4, 2017 (Actual)
Last update posted: Feb 14, 2018

2016 – 2017

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Raj K Maturi MD PC	Indianapolis	Indiana	46290	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02732899, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 14, 2018 · Synced Nov 14, 2026